CTL-associated antigen 4 (CTLA4) blockade releases inhibitory controls on T cell activation
and proliferation, inducing antitumor immunity in both preclinical and early clinical trials. We …

Anti-CTLA-4 antibodies have successfully elicited durable tumor regression in the clinic;
however, long-term benefit is limited to a subset of patients for select cancer indications. The …

Accumulating data indicate that tumor-infiltrating regulatory T cells (Treg) are present in
human tumors and locally suppress antitumor immune cells. In this study, we found an …

Immune checkpoint inhibitors such as anti–CTLA-4 antibody are widely accepted
therapeutic options for many cancers, but there is still a considerable gap in achieving their …

Treatment with monoclonal antibody specific for cytotoxic T lymphocyte–associated antigen
4 (CTLA-4), an inhibitory receptor expressed by T lymphocytes, has emerged as an effective …

Cytotoxic T lymphocyte–associated antigen 4 (CTLA4) delivers inhibitory signals to activated
T cells. CTLA4 is constitutively expressed on regulatory CD4+ T cells (Tregs), but its role in …

Cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) is a critical negative regulator of
immune responses. Uniquely among known inhibitory receptors, its genetic ablation results …

Purpose: Blockade of CTL-associated antigen-4 (CTLA-4), an inhibitory immunomodulatory
molecule on T cells, has been shown to enhance T-cell responses and induce tumor …

Antibodies targeting CTLA-4 induce durable responses in some patients with melanoma
and are being tested in a variety of human cancers. However, these therapies are ineffective …

Anti–CTLA-4 mAb is efficacious in enhancing tumor immunity in humans. CTLA-4 is
expressed by conventional T cells upon activation and by naturally occurring FOXP3+ CD4+ …